Adverse effects during endocrine therapy for prostatic carcinoma with a high dose of estrogen.
A clinical study of the adverse effects induced by the endocrine therapy with a high dose of estrogen in 45 patients with stage C or D prostatic carcinoma is conducted. Transient decreases of hemoglobin and serum protein values were observed after administration of estrogen. The levels of glutamine-oxaloacetic and glutamic-pyruvic transaminase showed a transient increase. The value of serum total cholesterol and electrolytes showed no changes. Serial evaluations of electrocardiograms have played a minor role in the observation of cardiovascular disease. Up to date we have not experienced cardiovascular death in our cases during the endocrine therapy.
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002369:Castration; D002784:Cholesterol / Q000097:blood; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced; D004562:Electrocardiography; D004573:Electrolytes / Q000097:blood; D006452:Hemoglobinometry; D006801:Humans; D007275:Injections, Intravenous; D002542:Intracranial Embolism and Thrombosis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004573:Electrolytes; D004054:Diethylstilbestrol; D002784:Cholesterol; C004955:fosfestrol